Business Development Archives | Report Store

show blocks helper

Sort by Default Order
- Default Order
- Name
- Price
- Date
- Popularity

Click to order products descending

Display 15 Products per page

Bayer’s Consumer Chief Initiates Turnaround Plan In Bid To Return Troubled Business To Growth

$200.00

Bayer AG is seeking to turn around its troubled Consumer Health division through implementing key portfolio changes and embracing growth-focused innovation, according to Heiko Schipper, President of Consumer Health. Find out what’s in store for Bayer AG’s Consumer Health group, straight from its top leadership.
December 17, 2018
Find out more
Novartis Pruned Pipeline Producing Attractive Respiratory And Neurology Fruits

$200.00

In the wake of new CEO Vas Narasimhan, and like several of its peers in the industry, Novartis AG recently announced it was paring back their pipeline, from 430 products to 340. Find out which products got the axe and what the focus of the company will be in the months and years to come in this illuminating article from Scrip.
December 13, 2018
Find out more
Father of Humira, Greg Winter, Wins 2018 Nobel Prize For Chemistry

$131.00

The 2018 Nobel Prize for Chemistry was recently jointly awarded to George Winter and two other scientists for their pioneering work in the directed evolution of antibodies, research which led to the development of Humira, the world’s most successful drug.
December 9, 2018
Find out more
Poseida, Legend/Janssen Look To Snag Celgene/ Bluebird’s BCMA Crown

$200.00

The BCMA CAR-T therapies gap between industry leaders Celgene and bluebird bio and their competition in the space is closing, according to data released at the December 2018 American Society of Hematology (ASH) meeting in San Diego.
December 4, 2018
Find out more
Analysts Weigh Up Benefits Of Big Bayer Restructuring

$131.00

The recent shakeup at Bayer AG took some observers by surprise, but was heralded by most as a much-needed measure to maintain the German giant’s viability. Find out how this restructuring will play out, and what top analysts make of the move to streamline the organization.
November 30, 2018
Find out more
R&D Heads At GSK & AZ Say Key To Success Lies In Smart Risk Taking

$131.00

What’s the secret to successfully transforming research and development innovation into drug launches? Taking risks, but doing so in a focused, smarter way, say the heads of Britain’s two largest pharma companies. Read more about the secrets to their success here.
November 15, 2018
Find out more
P&G Grooming Quits Counting Blades, Innovates In New Directions While Battling DTC Disruptors

$200.00

In the wake of the disruptive influence of Dollar Shave Club, Proctor & Gamble’s Grooming business is making progress in its efforts to win back market share, slowly, but surely. During an Investor Day presentation, P&G’s global division president also warned that there were likely to be hiccups during the recovery process.
November 13, 2018
Find out more
New Year Present For Takeda As Shire Close Nears?

$131.00

The wheels are turning for Takeda’s huge acquisition of Shire, assuming the European Commission’s approval on antitrust concerns, and the approval of the respective companies’ stakeholders. The $62.4b deal is the biggest overseas M&A deal in Japanese history, and brings with it speculation of future divestments by Takeda.
November 12, 2018
Find out more
AbbVie Hit Harder By EU Humira Biosimilars Than Projected

$131.00

AbbieVie’s Q3 earnings call was a chance for analysts and investors to ask tough questions about the worse-than-projected impact of the first adalimumab (Humira) biosimilars to hit the European markets. Executives remained optimistic for the future of the blockbuster drug and the financial well-being of the company.
November 2, 2018
Find out more
Focus More On Patients, Less On Hospitals, Experts Tell Device Companies

$131.00

Several medtech industry experts sat down with Medtech Insight to share their views on how the medical devices industry can remain competitive in a shifting healthcare climate by moving its focus to serving patients, rather than catering to doctors and hospitals.
November 1, 2018
Find out more
DECIEM, Truly ‘The Abnormal Beauty Company,’ Faces Uncertain Future

$131.00

“Almost everyone at Deciem has been involved in a major criminal activity.” So claimed Deciem Inc. founder Brandon Truaxe on an October 8 Instagram post in which he also announced the controversial Estee Lauder Companies-backed startup would be ceasing operations “until further notice.” Find out more here.
October 9, 2018
Find out more
The Blockbusters No One Talks About

$131.00

Although their patent protection has expired, big-name blockbusters continue to produce huge revenues for the pharmaceutical companies that produce them. Take a look at how some well-known drugs may no longer be making headlines, but continue to be big earners.
June 21, 2018
Find out more
Cosmetic Preservatives Crisis Creeping Into CIR Program

$131.00

The assessment of cosmetic preservative safety continues to be complex and fraught with controversy, as some in the industry look to the Cosmetic Ingredient Review (CIR) program to set the record straight about the use of certain cosmetic preservative ingredients.
June 10, 2018
Find out more
Colgate/Tom’s Of Maine Pays Back Unilever For ‘Naturally Dry’ Loss

$131.00

It’s payback time for Unilever, as the maker of Schmidt’s deodorants must re-label its products, removing reference to certain wetness-absorption claims. In 2016, Unilever was responsible for making close competitor Colgate’s Tom’s of Maine remove similar claims to their deodorant products at a self-regulatory forum.
June 7, 2018
Find out more
Estee Lauder Is Revising Claims, Retesting Products After Internal Breakdown

$131.00

Estée Lauder’s CEO revealed that “a small group of employees” was responsible for intentionally altering test results behind product claims. The shocking disclosure was mitigated by the fact that the problem was discovered internally. Nevertheless, stock tumbled following the announcement–but has largely recovered. Find out how the disclosure may affect Lauder moving forward, and learn how analysts reacted
May 16, 2018
Find out more

Business Development

Business Development

Bayer’s Consumer Chief Initiates Turnaround Plan In Bid To Return Troubled Business To Growth

Novartis Pruned Pipeline Producing Attractive Respiratory And Neurology Fruits

Father of Humira, Greg Winter, Wins 2018 Nobel Prize For Chemistry

Poseida, Legend/Janssen Look To Snag Celgene/ Bluebird’s BCMA Crown

Analysts Weigh Up Benefits Of Big Bayer Restructuring

R&D Heads At GSK & AZ Say Key To Success Lies In Smart Risk Taking

P&G Grooming Quits Counting Blades, Innovates In New Directions While Battling DTC Disruptors

New Year Present For Takeda As Shire Close Nears?

AbbVie Hit Harder By EU Humira Biosimilars Than Projected

Focus More On Patients, Less On Hospitals, Experts Tell Device Companies

DECIEM, Truly ‘The Abnormal Beauty Company,’ Faces Uncertain Future

The Blockbusters No One Talks About

Cosmetic Preservatives Crisis Creeping Into CIR Program

Colgate/Tom’s Of Maine Pays Back Unilever For ‘Naturally Dry’ Loss

Estee Lauder Is Revising Claims, Retesting Products After Internal Breakdown